EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Cross-border molecular epidemiology of Plasmodium falciparum drug susceptibility: insights from the Uganda–Democratic Republic of the Congo border

Patrick Mamona Dilufwasayo, Betty Balikagala, Moise Agenowun Uchopa, Jacques Amanga Amaa, Dieudonné Mumba Ngoyi, Toshihiro Mita

Malaria Journal · 2026

DOI: 10.1186/s12936-026-05929-6 ↗

At a glance

Journal article in Malaria Journal, 2026. Written by Patrick Mamona Dilufwasayo and 5 co-authors. Institution: Department of Tropical Medicine and Parasitology, School of Medicine, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-84…. Major MEDLINE topics: Plasmodium falciparum, Drug Resistance, Malaria, Falciparum, Antimalarials. Cited 1 times so far (Crossref); 64 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Grants-in-aid for scientific research.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

BACKGROUND: Cross-border parasite movement drives resistance emergence in endemic regions. In Uganda, Plasmodium falciparum with artemisinin partial resistance emerged early and spread rapidly, making it a focal point for surveillance. In northeastern Democratic Republic of Congo (DRC), a key trade corridor bordering Uganda, we investigated molecular markers of artemisinin partial resistance and resistance to partner drugs used in artemisinin-based combination therapies (ACTs). Monitoring these resistance markers in DRC is essential for guiding regional containment efforts. METHODS: From May to June 2023, we conducted active and passive malaria case detection in 20 villages and a central hospital, respectively. Molecular analyses included copy number variation (CNV) in pfmdr1 and pfpm2/3, and genotyping of pfkelch13, pfmdr1, and pfcrt. For pfmdr1 CNV determination, we adopted a quantitative real-time PCR threshold of 1.4, recently proposed for parasite populations with frequent multiclonal infections. Whole-genome sequencing (WGS) was performed on hospital-derived samples to assess parasite relatedness and trace resistance spread. RESULTS: Among the 536 individuals sampled from the villages, 49.8% tested positive for P. falciparum by PCR. The pfmdr1 N86 allele was fixed, and 50.3% of samples carried the NFD haplotype (amino acid positions 86, 184, and 1246), a marker associated with reduced lumefantrine susceptibility in Africa. Pfmdr1 CNV was detected in 4.4% of samples using the conventional threshold (≥ 1.5), increasing to 11.7% with the 1.4 threshold. Pfpm2/3 CNVs, which may influence piperaquine susceptibility, were identified in 7.0% of samples. The validated pfkelch13 mutations A675V and C469Y, associated with artemisinin partial resistance, were detected in 4.3% and 1.3% of village samples, respectively. Principal component analysis of WGS data showed that DRC parasites carrying A675V or C469Y clustered closely with Ugandan strains, supporting cross-border spread of resistant parasites between DRC and Uganda. CONCLUSION: Our findings identified the presence of molecular markers associated with artemisinin partial resistance and reduced susceptibility to lumefantrine in northeastern DRC, along with evidence of cross-border parasite migration from Uganda. Given opposing selection pressures of lumefantrine and amodiaquine on pfmdr1 and pfcrt, alternative ACTs such as artesunate-amodiaquine may merit further evaluation. To sustain ACT efficacy, integrated genomic surveillance, clinical monitoring, and coordinated regional policy responses are essential.

Subjects

MeSH terms (MEDLINE)

Plasmodium falciparumDrug ResistanceMalaria, FalciparumAntimalarialsArtemisininsUgandaDemocratic Republic of the CongoHumansMolecular EpidemiologyDNA Copy Number VariationsGenotype

Author keywords

Pfcrt, plasmepsin 2/3Plasmodium falciparumpfkelch13pfmdr1Drug resistanceMolecular surveillance

Substances

AntimalarialsArtemisinins

Authors and institutions

  • Department of Tropical Medicine and Parasitology, School of Medicine, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
  • Department of Tropical Medicine and Parasitology, School of Medicine, University of Kinshasa, B.P. 127 Kinshasa XI, Lemba, Democratic Republic of Congo.
  • Department of Tropical Medicine and Parasitology, School of Medicine, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. b-betty@juntendo.ac.jp.
  • General Hospital of Aru, Essefe, Aru, Turi, Democratic Republic of Congo.
  • Aru Health District, Essefe, Aru, Ituri, Democratic Republic of Congo.
  • Department of Parasitology, National Institute of Biomedical Research (INRB), 5345 Avenue de La Démocratie, Gombe, Kinshasa, Democratic Republic of Congo.

Funding

  • Grants-in-aid for scientific research

Cite

APA

Dilufwasayo, P. M., Balikagala, B., Uchopa, M. A., Amaa, J. A., Ngoyi, D. M., & Mita, T. (2026). Cross-border molecular epidemiology of Plasmodium falciparum drug susceptibility: insights from the Uganda–Democratic Republic of the Congo border. Malaria Journal. https://doi.org/10.1186/s12936-026-05929-6

Vancouver

Dilufwasayo PM, Balikagala B, Uchopa MA, Amaa JA, Ngoyi DM, Mita T. Cross-border molecular epidemiology of Plasmodium falciparum drug susceptibility: insights from the Uganda–Democratic Republic of the Congo border. Malaria Journal. 2026. doi:10.1186/s12936-026-05929-6

BibTeX
@article{Dilufwasayo2026,
  author = {Dilufwasayo, Patrick Mamona and Balikagala, Betty and Uchopa, Moise Agenowun and Amaa, Jacques Amanga and Ngoyi, Dieudonné Mumba and Mita, Toshihiro},
  title = {Cross-border molecular epidemiology of Plasmodium falciparum drug susceptibility: insights from the Uganda–Democratic Republic of the Congo border},
  journal = {Malaria Journal},
  year = {2026},
  doi = {10.1186/s12936-026-05929-6}
}
Start for free →